Your browser doesn't support javascript.
loading
Identification of early predictive imaging biomarkers and their relationship to serological angiogenic markers in patients with ovarian cancer with residual disease following cytotoxic therapy.
Mitchell, C L; O'Connor, J P B; Jackson, A; Parker, G J M; Roberts, C; Watson, Y; Cheung, S; Davies, K; Buonaccorsi, G A; Clamp, A R; Hasan, J; Byrd, L; Backen, A; Dive, C; Jayson, G C.
Afiliación
  • Mitchell CL; Cancer Research UK, Department of Medical Oncology, Christie Hospital and University of Manchester. Electronic address: cmitchell@picr.man.ac.uk.
  • O'Connor JPB; Cancer Research UK, Department of Medical Oncology, Christie Hospital and University of Manchester; Imaging Science and Biomedical Engineering Department, School of Cancer and Imaging Sciences, University of Manchester.
  • Jackson A; Imaging Science and Biomedical Engineering Department, School of Cancer and Imaging Sciences, University of Manchester.
  • Parker GJM; Imaging Science and Biomedical Engineering Department, School of Cancer and Imaging Sciences, University of Manchester.
  • Roberts C; Imaging Science and Biomedical Engineering Department, School of Cancer and Imaging Sciences, University of Manchester.
  • Watson Y; Imaging Science and Biomedical Engineering Department, School of Cancer and Imaging Sciences, University of Manchester.
  • Cheung S; Imaging Science and Biomedical Engineering Department, School of Cancer and Imaging Sciences, University of Manchester.
  • Davies K; Imaging Science and Biomedical Engineering Department, School of Cancer and Imaging Sciences, University of Manchester.
  • Buonaccorsi GA; Imaging Science and Biomedical Engineering Department, School of Cancer and Imaging Sciences, University of Manchester.
  • Clamp AR; Cancer Research UK, Department of Medical Oncology, Christie Hospital and University of Manchester.
  • Hasan J; Cancer Research UK, Department of Medical Oncology, Christie Hospital and University of Manchester.
  • Byrd L; Cancer Research UK, Department of Medical Oncology, Christie Hospital and University of Manchester.
  • Backen A; Department of Clinical and Experimental Pharmacology, Paterson Institute for Cancer Research, University of Manchester, Manchester, UK.
  • Dive C; Department of Clinical and Experimental Pharmacology, Paterson Institute for Cancer Research, University of Manchester, Manchester, UK.
  • Jayson GC; Cancer Research UK, Department of Medical Oncology, Christie Hospital and University of Manchester; Department of Clinical and Experimental Pharmacology, Paterson Institute for Cancer Research, University of Manchester, Manchester, UK.
Ann Oncol ; 21(10): 1982-1989, 2010 Oct.
Article en En | MEDLINE | ID: mdl-20351070
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Neoplasias Peritoneales / Protocolos de Quimioterapia Combinada Antineoplásica / Biomarcadores de Tumor / Cistadenocarcinoma Seroso / Neoplasia Residual / Recurrencia Local de Neoplasia Tipo de estudio: Diagnostic_studies / Prognostic_studies / Risk_factors_studies Límite: Female / Humans Idioma: En Revista: Ann Oncol Asunto de la revista: NEOPLASIAS Año: 2010 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Neoplasias Peritoneales / Protocolos de Quimioterapia Combinada Antineoplásica / Biomarcadores de Tumor / Cistadenocarcinoma Seroso / Neoplasia Residual / Recurrencia Local de Neoplasia Tipo de estudio: Diagnostic_studies / Prognostic_studies / Risk_factors_studies Límite: Female / Humans Idioma: En Revista: Ann Oncol Asunto de la revista: NEOPLASIAS Año: 2010 Tipo del documento: Article